(Q37776316)

23 August 2017

1 reference

title

Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION (English)

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

12 June 2024

author name string

Jeffrey McCullough

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20667041

12 June 2024

publication date

1 December 2010

1 reference

full work available at URL

23 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1537-2995.2010.02787.x

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1537-2995.2010.02787.x

12 June 2024

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

12 June 2024

1 reference

23 August 2017

volume

50

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

2542-2546

1 reference

Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2010.02787.X

Isoimmune neonatal neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2010.02787.X

Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2010.02787.X

The new generation of blood components.

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

The National Marrow Donor Program with emphasis on the early years

12 June 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Nonhemolytic febrile transfusion reactions. Quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes

12 June 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

The role of the plasma from platelet concentrates in transfusion reactions

12 June 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

12 June 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Graft versus host reaction in Wiskott-Aldrich syndrome: antemortem diagnosis of human GVH in an immunologic deficiency disease.

12 June 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Irradiation of blood products. Indications and guidelines

12 June 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Donor-derived alloantibodies and passenger lymphocyte syndrome in two of four patients who received different organs from the same donor

12 June 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Nomenclature of human platelet antigens

12 June 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia

12 June 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Successful transfusion of platelets “mismatched” for HLA antigens to alloimmunized thrombocytopenic patients

12 June 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Monetary blood donation incentives and the risk of transfusion-transmitted infection.

12 June 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group

12 June 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

12 June 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Recombinant human erythropoietin and its role in transfusion medicine

12 June 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Intravenous immune globulins: an update for clinicians

12 June 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A.

12 June 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Thirty-five years of Rh prophylaxis

12 June 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Evaluating transfusion triggers

12 June 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

12 June 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Improvement of Kidney-Graft Survival with Increased Numbers of Blood Transfusions

12 June 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: do we have the answers yet?

12 June 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Emerging infections--another warning.

12 June 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections

12 June 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

12 June 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference

12 June 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Collection of two units of leukoreduced RBCs from a single donation with a portable multiple-component collection system

12 June 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies

12 June 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

The role of physicians in blood centers.

12 June 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2010.02787.X

12 June 2024

Identifiers

1 reference

23 August 2017

1 reference